Rising prostate-specific antigen after primary prostate cancer therapy

Area of Science:

• Oncology
• Urology

Background:

• Biochemical recurrence (BCR) after prostate cancer treatment affects 20-40% of men within 10 years.
• Prostate-specific antigen (PSA) kinetics, rather than absolute levels, may be a more crucial predictor of disease progression and survival.
• Therapeutic interventions for BCR should carefully weigh the risk of disease progression against treatment-related morbidity.

Purpose of the Study:

• To review the current landscape of managing early, asymptomatic prostate cancer recurrence.
• To evaluate the efficacy and limitations of various treatment modalities for BCR.
• To highlight the need for evidence-based approaches considering patient quality of life.

Main Methods:

• Review of existing literature on prostate cancer recurrence and treatment strategies.
• Analysis of data regarding PSA kinetics as a predictive marker.
• Evaluation of salvage radiation therapy, hormonal therapies, and emerging non-traditional treatments.

Main Results:

• Salvage radiation therapy shows variable long-term biochemical control rates (18-64%).
• Early hormonal therapy may delay metastasis but carries significant adverse effects.
• Non-steroidal antiandrogens show promise for preserving sexual function but have conflicting long-term outcome data.
• Non-traditional therapies lack robust evidence for improving progression-free or cancer-specific survival despite favorable safety profiles.

Conclusions:

• Management of early BCR requires careful consideration of individual patient factors and risk stratification.
• Further research is needed to establish the efficacy of novel therapies for BCR.
• Optimizing treatment strategies for BCR is crucial to improve long-term outcomes and quality of life for prostate cancer survivors.